- Global Pharma News & Resources

Visiongain publishes Global Biosimilars and Follow-On Biologics Market 2020-2030 report

Monoclonal Antibodies (mAbs), Fusion Proteins, Insulin, Erythropoietin's, Granulocyte Colony-Stimulating Factor (G-CSF), Interferons, Growth Hormones, Fertility Hormones, Blood Disorders, Growth Hormone Deficiency, Autoimmune Diseases, Cancer, Diabetes, Infectious Diseases

LONDON, Aug. 26, 2020 /PRNewswire/ -- The global biosimilars and follow-on biologics market is estimated to have reached $19.87bn in 2019 and expected to grow at a CAGR of 7.1% in the first half of the forecast period. The market is dominated by Biosimilar Monoclonal Antibodies, this submarket is estimated to hold 36.5% share of this market in 2020.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 420-page report you will receive 131 tables and 90 figures– all unavailable elsewhere.

The 420-page Visiongain report provides clear detailed insight into the global biosimilars and follow-on biologics market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

To request sample pages from this report please email or refer to our website:

Report Scope

• Global Biosimilars and Follow-on Biologics Market forecasts from 2020-2030

• Along with revenue prediction for the overall world market for biosimilars, our investigation shows forecasts to 2029 for 8 individual therapeutic submarkets:

• Monoclonal antibodies (mAbs)

• Fusion proteins

• Insulin

• Erythropoietin (EPO)

• Granulocyte colony-stimulating factor (G-CSF)

• Interferons

• Growth hormones

• Fertility hormones

• This report also shows revenue to 2030 for 11 individual submarkets within the above segments:

• Rituximab, infliximab, trastuzumab, adalimumab and bevacizumab

• Human insulin, insulin analogues, insulin glargine and insulin lispro

• Interferon alfa and interferon beta

• Our analyses show individual revenue forecasts to 2030 for 17 national markets:

• US

• Canada

• Japan

• Germany

• France

• UK

• Italy

• Spain

• Sweden

• Norway

• China

• India

• South Korea

• Russia

• Brazil

• South Africa

• Australia

• Our study discusses the leading companies that are involved in the biosimilars and follow-on biologics industry:

• Amgen Inc

• Biocon Limited

• Celltrion Healthcare Co. Ltd

• Dong-A Socio Holdings Co. Ltd

• Dr.Reddy's Labs (DRL)

• & Other Companies

• Our study provides a SWOT analysis of the biosimilars and follow-on biologics market.

• Our study discusses pressures, opportunities and other events affecting the biosimilars industry and market, including these influences:

• Strategies for developing biosimilars – needs, demand, challenges and opportunities

• Guidelines from regulators (FDA, EMA and others)

• Patent challenges and data exclusivity for biopharmaceuticals

• Needs and opportunities in developing biosimilar mAbs, including rising incidence of cancers and increasing demand for lower-cost biologicals

• Developments in technology and operations for biosimilar drug production.

To request a report overview of this report please email or refer to our website:

Did you know that we also offer a report add-on service? Email to discuss any customized research needs you may have.

Companies covered in the report include:

Amgen Inc.

Biocon Limited



BioXpress Therapeutics

Boehringer Ingelheim

Bristol-Myers Squibb

Cell Therapeutics

Celltrion Healthcare Co. Ltd.

Dong-A Socio Holdings

Dr. Reddy's Laboratories Ltd.



Epirus Biopharmaceuticals



Fujifilm Kyowa Kirin Biologics

F Hoffmann-La Roche Ltd.

Gedeon Richter Plc


Hanwha Chemical

Harvest Moon




IBSS Biomed

ImClone LLC

Instituto Vital Brazil


Isu Abxis


Johnson & Johnson

Kyowa Hakko Kirin

Laboratorios Liomont

Intas Pharmaceuticals

LG Life Sciences


Merck Serono

Millhouse LLC

Mitsubishi Tanabe

Mochida Pharmaceutical

Mustafa Nevzat Pharmaceuticals

Natco Pharma

Nichi-Iko Pharmaceutical Co.

Mylan N.V.

Nippon Kayaku Co. Ltd.

Pfizer Inc.



Reliance Life Sciences


Samsung Bioepis




Seattle Genetics

Shanghai CP Guojian



Spectrum Pharmaceuticals

Stada Arzneimittel AG

Teva Pharmaceutical Industries Ltd.


União Química


Walvax Biotechnology



Zhejiang Huahai Pharmaceutical

Wockhardt Limited

Zydus Cadila group

List of Organizations Mentioned in the Report

Agence française de sécurité sanitaire des produits de santé (ANSM)

Agência Nacional de Vigilância Sanitária (ANVISA)

Chinese Centre for Drug Evaluation (CDE)

Cour des Comptes (France)

European Medicines Agency (EMA)

Food and Drug Administration (US FDA)

Fraunhofer Center for Molecular Biology

Health Canada

India Brand Equity Foundation

Korean Food and Drug Administration (KFDA)

Medicines and Healthcare Products Regulatory Agency (MHRA)

Ministry of Food and Drug Safety (South Korea)

Ministry of Health (Russia)

Ministry of Health, Labour and Welfare (MHLW)

National Institute for Health and Care Excellence (NICE)

National Institute for Health Research Horizon Scanning Centre

Norwegian Medical Agency

Russian Ministry of Health

Scientific Centre for Expertise of Medicinal Application Products (Russia)

Spanish Ministry of Health

State Food and Drug Administration (SFDA)

The Cancer Centre Bahamas

Washington Legal Foundation

World Health Organization (WHO)

To see a report overview please e-mail


Global Biosimilar Monoclonal Antibodies Forecast 2020-2030

Biological Drug API Manufacturing Services World Industry and Market Forecast to 2029

Global Bioreactors Market 2020-2030

Translational Regenerative Medicine Market Forecast 2020-2030

Global Rheumatoid Arthritis Drugs Market Forecast 2020-2030


Visiongain publishes Global Biosimilars and Follow-On Biologics Market 2020-2030 report

Editor Details

Last Updated: 26-Aug-2020